ALK and non-small cell lung carcinoma: In addition, the combination of targeted therapy and chemotherapy has also achieved good efficacy in some NSCLC patients with epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusions.